Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics

NCT03985384 is registered in ClinicalTrials.gov with Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center as lead sponsor.

NCT NCT03985384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03985384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2019
Completion date
December 27, 2022
Enrollment
140 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, type 2 diabetes